Literature DB >> 12082543

Mouse models of neurofibromatosis 1 and 2.

David H Gutmann1, Marco Giovannini.   

Abstract

The neurofibromatoses represent two of the most common inherited tumor predisposition syndromes affecting the nervous system. Individuals with neurofibromatosis 1 (NF1) are prone to the development of astrocytomas and peripheral nerve sheath tumors whereas those affected with neurofibromatosis 2 (NF2) develop schwannomas and meningiomas. The development of traditional homozygous knockout mice has provided insights into the roles of the NF1 and NF2 genes during development and in differentiation, but has been less instructive regarding the contribution of NF1 and NF2 dysfunction to the pathogenesis of specific benign and malignant tumors. Recent progress employing novel mouse targeting strategies has begun to illuminate the roles of the NF1 and NF2 gene products in the molecular pathogenesis of NF-associated tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082543      PMCID: PMC1531708          DOI: 10.1038/sj.neo.7900249

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  105 in total

Review 1.  Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force.

Authors:  K N North; V Riccardi; C Samango-Sprouse; R Ferner; B Moore; E Legius; N Ratner; M B Denckla
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

2.  A mouse model for the learning and memory deficits associated with neurofibromatosis type I.

Authors:  A J Silva; P W Frankland; Z Marowitz; E Friedman; G S Laszlo; D Cioffi; T Jacks; R Bourtchuladze; G Lazlo
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

3.  Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase.

Authors:  H A Kim; B Ling; N Ratner
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

4.  Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.

Authors:  R Listernick; D N Louis; R J Packer; D H Gutmann
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

5.  Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia.

Authors:  D A Largaespada; C I Brannan; N A Jenkins; N G Copeland
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

6.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Authors:  G Bollag; D W Clapp; S Shih; F Adler; Y Y Zhang; P Thompson; B J Lange; M H Freedman; F McCormick; T Jacks; K Shannon
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

7.  Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons.

Authors:  K S Vogel; C I Brannan; N A Jenkins; N G Copeland; L F Parada
Journal:  Cell       Date:  1995-09-08       Impact factor: 41.582

8.  Nonrandom chromosomal gains in pilocytic astrocytomas of childhood.

Authors:  F V White; D C Anthony; E J Yunis; N J Tarbell; R M Scott; D E Schofield
Journal:  Hum Pathol       Date:  1995-09       Impact factor: 3.466

9.  Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes.

Authors:  H A Kim; T Rosenbaum; M A Marchionni; N Ratner; J E DeClue
Journal:  Oncogene       Date:  1995-07-20       Impact factor: 9.867

10.  Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.

Authors:  T Rosenbaum; Y L Boissy; K Kombrinck; C I Brannan; N A Jenkins; N G Copeland; N Ratner
Journal:  Development       Date:  1995-11       Impact factor: 6.868

View more
  25 in total

Review 1.  Mouse models of inherited cancer syndromes.

Authors:  Sohail Jahid; Steven Lipkin
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

Review 2.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

3.  Giant thoracic schwannoma in a rhesus macaque (Macaca mulatta).

Authors:  Derron A Alves; Todd M Bell; Carrie Benton; Elisabeth J Rushing; Edward L Stevens
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-11       Impact factor: 1.232

4.  Perfusion single photon emission computed tomography in a mouse model of neurofibromatosis type 1: towards a biomarker of neurologic deficits.

Authors:  Ivayla Apostolova; Dagmara Niedzielska; Thorsten Derlin; Eva J Koziolek; Holger Amthauer; Benedikt Salmen; Jens Pahnke; Winfried Brenner; Victor F Mautner; Ralph Buchert
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-18       Impact factor: 6.200

5.  Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Authors:  Susan E Maloney; Krystal C Chandler; Corina Anastasaki; Michael A Rieger; David H Gutmann; Joseph D Dougherty
Journal:  Autism Res       Date:  2017-08-26       Impact factor: 5.216

6.  Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.

Authors:  Georgette N Jones; Chhavy Tep; William H Towns; Georgeta Mihai; Ian D Tonks; Graham F Kay; Petra M Schmalbrock; Anat O Stemmer-Rachamimov; Sung Ok Yoon; Lawrence S Kirschner
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

7.  Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

Authors:  S Prabhakar; G J Brenner; B Sung; S M Messerli; J Mao; M Sena-Esteves; A Stemmer-Rachamimov; B Tannous; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2009-10-16       Impact factor: 5.987

8.  PTEN dosage is essential for neurofibroma development and malignant transformation.

Authors:  Caroline Gregorian; Jonathan Nakashima; Sarah M Dry; P Leia Nghiemphu; Kate Barzan Smith; Yan Ao; Julie Dang; Gregory Lawson; Ingo K Mellinghoff; Paul S Mischel; Michael Phelps; Luis F Parada; Xin Liu; Michael V Sofroniew; Fritz C Eilber; Hong Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-21       Impact factor: 11.205

9.  Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.

Authors:  Marianne F James; Johanna M Lelke; Mia Maccollin; Scott R Plotkin; Anat O Stemmer-Rachamimov; Vijaya Ramesh; James F Gusella
Journal:  Neurobiol Dis       Date:  2007-09-19       Impact factor: 5.996

10.  Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature.

Authors:  Anandh Balasubramaniam; Patrick Shannon; Mojgan Hodaie; Normand Laperriere; Howard Michaels; Abhijit Guha
Journal:  Neuro Oncol       Date:  2007-08-17       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.